酪氨酸激酶抑制剂伊马替尼对于断裂点集中区/艾贝尔森（Bcr-Abl）阳性白血病有着显著的治疗效果，但由于抗药性的原因影响了其在临床上的应用。作为第二代Bcr-Abl酪氨酸激酶抑制剂巴氟替尼在一系列临床前和临床后研究中表现出了良好的应用前景。

Although the tyrosine kinase inhibitor imatinib has the obvious efficacy on breakpoint cluster region-Abelson (Bcr-Abl) leukemia. However, clinical application is limited due to its drug-resistance. As the second generation Bcr-Abl tyrosine kinase inhibitor, bafetinb has a bright prospect in before and after clinical research.